Jacobs Levy Equity Management Inc. Buys Shares of 229,369 Nurix Therapeutics, Inc. (NASDAQ:NRIX)

Jacobs Levy Equity Management Inc. acquired a new position in shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX - Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 229,369 shares of the company's stock, valued at approximately $4,321,000. Jacobs Levy Equity Management Inc. owned about 0.30% of Nurix Therapeutics as of its most recent SEC filing.

Other large investors have also recently bought and sold shares of the company. US Bancorp DE raised its position in Nurix Therapeutics by 144.7% in the fourth quarter. US Bancorp DE now owns 1,424 shares of the company's stock valued at $27,000 after purchasing an additional 842 shares during the last quarter. Aquatic Capital Management LLC bought a new position in Nurix Therapeutics in the fourth quarter valued at about $87,000. Summit Investment Advisors Inc. raised its position in shares of Nurix Therapeutics by 13.6% during the fourth quarter. Summit Investment Advisors Inc. now owns 7,345 shares of the company's stock worth $138,000 after acquiring an additional 877 shares during the last quarter. BNP Paribas Financial Markets bought a new position in shares of Nurix Therapeutics during the fourth quarter worth about $164,000. Finally, ADAR1 Capital Management LLC bought a new position in shares of Nurix Therapeutics during the fourth quarter worth about $207,000.

Nurix Therapeutics Stock Performance

Nurix Therapeutics stock traded up $0.09 during mid-day trading on Tuesday, reaching $9.60. The stock had a trading volume of 619,106 shares, compared to its average volume of 877,930. The firm has a market capitalization of $731.48 million, a PE ratio of -3.32 and a beta of 2.23. Nurix Therapeutics, Inc. has a fifty-two week low of $8.18 and a fifty-two week high of $29.56. The stock's 50-day simple moving average is $10.97 and its 200-day simple moving average is $16.70.

Nurix Therapeutics (NASDAQ:NRIX - Get Free Report) last announced its earnings results on Tuesday, April 8th. The company reported ($0.67) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.72) by $0.05. The company had revenue of $18.45 million for the quarter, compared to analysts' expectations of $12.78 million. Nurix Therapeutics had a negative return on equity of 53.65% and a negative net margin of 354.85%. During the same quarter in the previous year, the firm earned ($0.76) earnings per share. On average, research analysts forecast that Nurix Therapeutics, Inc. will post -2.99 earnings per share for the current fiscal year.

Insider Activity at Nurix Therapeutics

In related news, CFO Houte Hans Van sold 6,198 shares of Nurix Therapeutics stock in a transaction that occurred on Friday, May 2nd. The stock was sold at an average price of $11.33, for a total transaction of $70,223.34. Following the transaction, the chief financial officer now owns 33,724 shares of the company's stock, valued at $382,092.92. The trade was a 15.53% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, insider Gwenn Hansen sold 3,377 shares of Nurix Therapeutics stock in a transaction that occurred on Wednesday, April 30th. The shares were sold at an average price of $11.50, for a total value of $38,835.50. Following the transaction, the insider now directly owns 61,516 shares in the company, valued at approximately $707,434. The trade was a 5.20% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 17,838 shares of company stock valued at $221,500 over the last 90 days. Insiders own 7.40% of the company's stock.

Analyst Ratings Changes

A number of equities analysts have recently issued reports on NRIX shares. Needham & Company LLC restated a "buy" rating and set a $27.00 price objective on shares of Nurix Therapeutics in a research report on Tuesday, April 29th. Royal Bank of Canada lifted their target price on Nurix Therapeutics from $26.00 to $27.00 and gave the stock an "outperform" rating in a report on Wednesday, January 29th. Leerink Partnrs upgraded Nurix Therapeutics to a "hold" rating in a report on Monday, March 17th. Wells Fargo & Company lowered their target price on Nurix Therapeutics from $32.00 to $25.00 and set an "overweight" rating for the company in a report on Wednesday, April 9th. Finally, Morgan Stanley lifted their target price on Nurix Therapeutics from $16.00 to $17.00 and gave the stock an "equal weight" rating in a report on Monday, February 3rd. Three analysts have rated the stock with a hold rating and sixteen have given a buy rating to the stock. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $30.44.

About Nurix Therapeutics

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.